Moximed
Moximed is a private medical device company that developed the MISHA Knee System, the first FDA-authorized implantable shock absorber for medial knee osteoarthritis. It sells directly to hospitals, ambulatory surgery centers, and orthopedic surgeons through enterprise field sales.
- Company typePrivate
- Founded2008
- HeadquartersHayward, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Moximed does
Moximed is a privately held medical device company headquartered in Fremont, California that develops and commercializes the MISHA Knee System, the first and only FDA-authorized implantable shock absorber (ISA) for medial compartment knee osteoarthritis (OA). The device is a polymer-based mechanical implant placed extra-capsularly on the medial knee that reduces approximately 30% of peak knee force with every walking step, thereby relieving pain and improving function without bone cutting, weight-bearing restrictions, or removal of cartilage surfaces. Moximed received FDA De Novo marketing authorization in April 2023 and treated its first U.S. commercial patients in September 2023 at leading academic medical centers.
The company sells the MISHA Knee System through a direct enterprise field sales model, employing Territory Managers covering defined U.S. geographies (West, Pacific Northwest, Sacramento CA, Arizona, South Florida) who engage orthopedic surgeons and joint preservation specialists at hospitals, ambulatory surgery centers (ASCs), and orthopedic practices. The MISHA procedure is performed outpatient with an average admission-to-discharge time of approximately nine hours, and reimbursement is supported by CMS HCPCS C-Code C8003 (effective January 2025) and an AMA Category I CPT code (effective January 2027). The company has raised over $150M in cumulative disclosed venture financing across multiple rounds, with the most recent being a $91M Series D in August 2024 led by Elevage Medical Technologies (a Patient Square Capital platform), and is currently in a rapid commercial scale-up phase having appointed a new CEO (Christopher Gleason) in June 2024 alongside senior commercial leadership with track records at companies acquired by Boston Scientific ($850M for Relievant) and Teleflex ($1.1B for NeoTract).
Moximed firmographics
Firmographics- Name
- Moximed
- Legal name
- Moximed, Inc.
- Website
- https://moximed.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Moximed is a private medical device company that developed the MISHA Knee System, the first FDA-authorized implantable shock absorber for medial knee osteoarthritis. It sells directly to hospitals, ambulatory surgery centers, and orthopedic surgeons through enterprise field sales.
- Ownership category
- akta.pro rank
Moximed industry classification
Industry- Product category
- Orthopedic Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Pain Management (Spine & Musculoskeletal) (HLAKALAM)
Keywords
Where Moximed is headquartered
LocationHeadquarters
- HQ city
- Hayward
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Moximed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Others
Revenue model
- Medical Device Hardware Sales: Moximed generates revenue through the sale of the MISHA Knee System, an implantable medical device. The company sells directly to healthcare providers (hospitals, ambulatory surgery centers) through its commercial infrastructure of Territory Managers. Pricing is negotiated with healthcare institutions and healthcare systems. As a Class II/III medical device with FDA market authorization, the device is reimbursed through established healthcare coding (HCPCS C-Code C8003 assigned to APC 5116).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Medical device sold to healthcare providers |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Moximed product offering
Product offeringCore offering
Moximed develops and commercializes the MISHA Knee System, an FDA-authorized implantable shock absorber (ISA) for medial compartment knee osteoarthritis. The device is placed extra-capsularly on the medial knee and reduces approximately 30% of peak knee force with every walking step, providing pain relief and functional improvement for patients who have failed conservative or surgical treatment but are not ready for or unwilling to undergo total knee replacement. The system is sold to hospitals and ambulatory surgery centers through a direct enterprise sales force and is implanted on an outpatient basis with no bone cutting and no weight-bearing restrictions.
Product overview
Moximed is a medical device company offering a single core product: the MISHA Knee System. The MISHA Knee System is the world's first implantable shock absorber (ISA) for the treatment of medial compartment knee osteoarthritis (OA). It is a standalone implant designed for outpatient placement on the medial knee that unloads the joint by reducing approximately 30% of peak force with every walking step, thereby alleviating pain, improving function, and potentially delaying the need for total knee replacement. The company also provides associated resources including clinical data, patient materials, rehabilitation guidelines, and surgeon education materials to support the MISHA Knee System throughout the patient care lifecycle.
Differentiator
Problem solved
Functional benefit
Products and services
- MISHA Knee System The MISHA Knee System is an implantable shock absorber (ISA) that unloads the medial compartment of the knee, relieving pain and improving function in patients with medial knee osteoarthritis who have failed conservative treatments but are not ready for or unwilling to undergo joint replacement. The implant is placed extra-capsularly on the medial knee, reduces approximately 30% of peak knee force with every walking step, and is designed for outpatient implantation with no bone cutting or weight-bearing restrictions.
Quantifiable outcome
- 96% of patients achieved clinically meaningful pain relief at 5 years post-implant
- +7 more outcomes
Companies that use Moximed
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles2 records
Moximed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Moximed partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered advocacy partner, coding authority and reimbursement partner.
- Arthroscopy Association of North America (AANA)advocacy partnerAANA submitted CPT code application to AMA CPT Editorial Panel for the MISHA Knee System. Following comprehensive review of clinical evidence and engagement with membership of over 5,000 orthopedic surgeons, the AMA established Category I CPT code for the Implantable Shock Absorber (MISHA Knee System) effective January 1, 2027.
- American Medical Association (AMA)coding authorityAMA CPT Editorial Panel established Category I CPT code for the MISHA Knee System effective January 1, 2027. This designation will expand patient access to this treatment option.
- Centers for Medicare & Medicaid Services (CMS)reimbursement partnerCMS established HCPCS C-Code C8003 for the MISHA Knee System assigned to APC 5116 effective January 1, 2025. This enables hospital outpatient departments and ambulatory surgery centers to report implantation for Medicare patients.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
Moximed competitors and assessment
Company assessmentDirect peers
- Relievant Medsystems: Developer of the Intracept Procedure for vertebrogenic chronic low back pain — a minimally invasive implantable nerve-targeting therapy. Closely comparable to Moximed in being a niche orthopedic pain intervention that targets a 'treatment gap' population, pursued a similar commercial build-out, and was ultimately acquired by Boston Scientific for $850M, mirroring Moximed's likely strategic trajectory.
- SI-BONE: Pure-play, venture-backed orthopedic medtech that commercialized the iFuse Implant System for sacroiliac joint dysfunction — a minimally invasive, joint-preserving implant in a similar niche pain market. Highly comparable in business model (direct enterprise sales to surgeons, evidence-driven adoption, CPT-driven reimbursement), scale stage, and go-to-market motion.
- Vertos Medical: Commercial-stage medical device company with the mild Procedure for lumbar spinal stenosis (minimally invasive decompression). Comparable as a venture-backed orthopedic pain intervention that pursued physician-focused commercialization, CPT code development, and an outpatient/ASC-friendly procedure profile similar to MISHA.
- Intrinsic Therapeutics: Developer of the Barricaid annular closure device for spine disc herniation. Comparable as a venture-backed orthopedic implantable focused on joint/disc preservation, with a similar early-commercialization profile and direct sales motion to orthopedic specialists.
Broad incumbents
- Stryker: One of the largest orthopedic medtech majors with broad knee, hip, and sports medicine portfolios including Mako robotic knee arthroplasty. Relevant as the dominant incumbent whose total/partial knee replacement systems represent the alternative therapy MISHA is positioned to defer rather than replace.
- Zimmer Biomet: Global orthopedic major with leading knee arthroplasty franchises (Persona, Oxford). Directly comparable as the incumbent whose joint replacement volumes MISHA seeks to delay, and a likely strategic acquirer given the established knee OA commercial channel.
- Smith+Nephew: Orthopedic and sports medicine major with the Journey/Oxford knee systems plus a growing sports medicine and biologics portfolio. Comparable as a broad orthopedic incumbent competing in the same knee OA continuum and an active acquirer of adjacent technologies.
- DePuy Synthes (Johnson & Johnson): J&J's orthopedic medtech division with the Attune and SIGMA knee replacement systems. Comparable as a major knee replacement incumbent and one of the most likely strategic acquirers of joint-preserving technologies like MISHA given the J&J medtech acquisition history.
- Arthrex: Privately held sports medicine and orthopedic soft-tissue repair leader. Comparable as a broad orthopedic incumbent that competes for the same orthopedic surgeon mindshare, particularly around joint-preservation procedures and outpatient sports medicine workflows.
Emerging players
- CartiHeal (Smith+Nephew): Developer of the Agili-C cartilage repair implant for knee OA, acquired by Smith+Nephew in 2023. Comparable as an emerging joint-preservation implant targeting the knee OA treatment gap population that MISHA also serves, and useful as a recent comparable exit in the knee OA biologic/implant space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Moximed social profiles
Digital presenceMoximed compliance and trust
Trust signalCompliance2 records
Moximed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Moximed leadership team
Management profileNumber of profiles
Profiles14 records
Moximed funding detail
Funding detailFunding overview
Funding rounds9 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Moximed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Moximed
What does Moximed do?
Moximed develops and commercializes the MISHA Knee System, an FDA-authorized implantable shock absorber (ISA) for medial compartment knee osteoarthritis. The device is placed extra-capsularly on the medial knee and reduces approximately 30% of peak knee force with every walking step, providing pain relief and functional improvement for patients who have failed conservative or surgical treatment but are not ready for or unwilling to undergo total knee replacement. The system is sold to hospitals and ambulatory surgery centers through a direct enterprise sales force and is implanted on an outpatient basis with no bone cutting and no weight-bearing restrictions.
Is Moximed a public or private company?
Moximed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Moximed founded?
Moximed was founded in 2008. It employs 11 to 50 people.
Where is Moximed based?
Moximed is headquartered in Hayward, United States, in the North America region.
How does Moximed make money?
One revenue line is on record: medical Device Hardware Sales.
Who are Moximed's main competitors?
Direct peers on record are Relievant Medsystems, SI-BONE, Vertos Medical and Intrinsic Therapeutics. Broad incumbents are Stryker, Zimmer Biomet, Smith+Nephew, DePuy Synthes (Johnson & Johnson) and Arthrex. CartiHeal (Smith+Nephew) is listed as an emerging player.
Does Moximed have an API?
No public API is recorded for Moximed.
What industry is Moximed in?
Moximed's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAKALAM, Pain Management (Spine & Musculoskeletal). Its NAICS code is 339113 and its SIC code is 3842.